![](https://medcitynews.com/wp-content/uploads/sites/7/2016/07/tips.jpg)
A Tipping Point: Organ Shortages and the Future of Transplantation
Increasingly, more patients qualify for transplants, making organ shortages today’s most pressing issue.
Increasingly, more patients qualify for transplants, making organ shortages today’s most pressing issue.
As a heart transplant recipient less than three years out from quadruple organ failure, and a father of two young children, I'm not just hoping that modernization will save and extend more lives. I'm counting on it.
Zelis CEO Amanda Eisel shares her perspective on how the company is solving the problems of a fragmented health financial system to benefit all.
OmniLIfe Health, based in Lexington, Kentucky, won the MedCity News INVEST Pitch Perfect contest on May 23, beating five other payer/provider startups. The company works to streamline workflows for organ transplants.
Paragonix Technologies recently closed a $24 million Series B funding round. The Cambridge, Massachusetts-based company provides transplant centers and organ procurement organizations with medical devices designed for the preservation and transportation of donor organs.
Quell Therapeutics' $156 million Series B round comes as it prepares to advance to a clinical trial testing its lead regulatory T cell therapy candidate as way to prevent organ rejection in liver transplant patients. The progress is part of a growing field of Treg cell therapy developers that is becoming increasingly competitive.
Takeda Pharmaceutical won FDA approval for Livtencity, an antiviral developed to treat cytomegalovirus infection in transplant patients. The agency also approved an Aadi Biosciences drug, making it the first therapy authorized for treating a rare type of soft-tissue cancer.
A new report from Relatient, A Data-Driven Guide to Patient Access Succes, highlights how focusing on data accuracy and relevance can enhance the performance of healthcare practices.
A Novartis drug intended to prevent organ rejection has failed to beat out the standard of care therapy in a Phase 2 study in kidney transplant patients. Other clinical trial failures announced ahead of the Labor Day weekend include a Forte Biosciences atopic dermatitis drug, as well a cancer therapy from Takeda Pharmaceutical.
Three biotechs IPOs priced this week while one gene therapy developer postponed its plans. The biggest IPO belongs to Talaris Therapeutics, a company developing a cell therapy for organ transplant patients that could mean the end of lifelong immunosuppressive drugs that prevent rejection.
The standard for organ transplant is a plastic picnic cooler filled with ice. Boston-based TransMedics is one-upping this idea with a warm blood perfusion device - essentially keeping organs alive as they await transplant surgery.
A 6.6 pound baby girl sadly suffered irreparable brain damage in the womb, but for the first time in Britain, surgeons were able to transplant her kidneys, which were transplanted into a patient with renal failure, and liver cells, which were donated to a second recipient who had liver damage. Doctors tried to revive the […]